AXL Inhibition Specialist BerGenBio's $24m Private Placement To Fund Pipeline, Trials

BerGenBio CEO says the Norwegian biotech aims, either alone or in partnership, to develop and commercialize its lead asset through to marketing approval in a variety of cancers.